Abeona Therapeutics (NASDAQ:ABEO) Trading Down 4.5%

Share on StockTwits

Abeona Therapeutics Inc (NASDAQ:ABEO) shares fell 4.5% during trading on Thursday . The company traded as low as $2.42 and last traded at $2.32, 25,793 shares were traded during mid-day trading. A decline of 96% from the average session volume of 620,775 shares. The stock had previously closed at $2.43.

ABEO has been the topic of a number of recent research reports. Royal Bank of Canada reduced their price objective on Abeona Therapeutics to $16.00 and set a “positive” rating on the stock in a research note on Tuesday, August 13th. They noted that the move was a valuation call. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research note on Wednesday. Mizuho reaffirmed a “hold” rating and set a $4.00 price objective on shares of Abeona Therapeutics in a research note on Monday, September 23rd. Zacks Investment Research cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, ValuEngine raised Abeona Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $17.21.

The company has a debt-to-equity ratio of 0.06, a current ratio of 2.54 and a quick ratio of 2.54. The company has a market capitalization of $111.45 million, a P/E ratio of -1.82 and a beta of 1.95. The company has a 50 day moving average of $2.55 and a 200-day moving average of $4.61.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.13). Research analysts predict that Abeona Therapeutics Inc will post -1.78 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. grew its stake in shares of Abeona Therapeutics by 5.9% in the second quarter. BlackRock Inc. now owns 2,459,931 shares of the biopharmaceutical company’s stock worth $11,759,000 after purchasing an additional 137,558 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Abeona Therapeutics by 11.8% in the second quarter. Vanguard Group Inc. now owns 1,828,699 shares of the biopharmaceutical company’s stock worth $8,742,000 after purchasing an additional 193,618 shares during the last quarter. Rhenman & Partners Asset Management AB grew its stake in shares of Abeona Therapeutics by 54.1% in the third quarter. Rhenman & Partners Asset Management AB now owns 1,000,000 shares of the biopharmaceutical company’s stock worth $2,260,000 after purchasing an additional 350,877 shares during the last quarter. Northern Trust Corp grew its stake in shares of Abeona Therapeutics by 2.0% in the second quarter. Northern Trust Corp now owns 408,134 shares of the biopharmaceutical company’s stock worth $1,951,000 after purchasing an additional 7,824 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Abeona Therapeutics by 13.6% in the second quarter. Bank of New York Mellon Corp now owns 158,723 shares of the biopharmaceutical company’s stock worth $759,000 after purchasing an additional 19,009 shares during the last quarter. 58.71% of the stock is currently owned by institutional investors.

About Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

See Also: What is the quiet period?

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Dine Brands Global Inc  Director Sells $26,394.54 in Stock
Dine Brands Global Inc Director Sells $26,394.54 in Stock
Proteo  Stock Price Up 4%
Proteo Stock Price Up 4%
Mitsubishi Motors  Trading Down 3.9%
Mitsubishi Motors Trading Down 3.9%
Tremont Mortgage Trust  Sees Large Decline in Short Interest
Tremont Mortgage Trust Sees Large Decline in Short Interest
Puma AG Rudolf Dassler Sport  Stock Price Up 1.1%
Puma AG Rudolf Dassler Sport Stock Price Up 1.1%
Trillium Asset Management LLC Grows Position in CBRE Group Inc
Trillium Asset Management LLC Grows Position in CBRE Group Inc


 
© 2006-2019 Zolmax.